Restor3d, a Durham-based company specializing in the production of three-dimensional printed orthopedic implants, recently announced a significant milestone with the closure of a $104 million investment round. This funding includes a substantial contribution of $65 million from a global private equity firm, Partner Group, along with an additional $39 million from existing shareholders. The infusion of capital is intended to drive further product innovation, support commercial expansion, and enhance the provision of personalized orthopedic care.
The strategic decision by Partner Group to acquire a minority stake in restor3d underscores the increasing interest in leveraging 3D printing technologies within the healthcare sector. This investment follows a series of successful funding rounds for restor3d, including a recent $38 million venture capital injection from both existing and new investors. Noteworthy milestones in the company’s financial journey include a $70 million Series A funding round in 2024, comprising investments from private backers and debt financing.
Restor3d’s CEO, Kurt Jacobus, expressed enthusiasm about the collaboration with Partner Group, emphasizing the shared commitment to driving surgical innovations that enhance patient outcomes in joint replacement procedures. The company’s focus on addressing the limitations of traditional off-the-shelf orthopedic products by delivering customized, patient-specific implants has garnered praise from industry experts. By offering rapid and precise solutions tailored to individual anatomies, restor3d aims to elevate surgical precision and functionality, ultimately leading to improved patient recovery and quality of life.
Founded in 2017 as a spinout from Duke University, restor3d has established a reputation for developing cutting-edge musculoskeletal implants through a blend of proprietary design software, vertically integrated manufacturing processes, and close collaboration with orthopedic professionals and medical institutions. Among its flagship products are a total knee replacement system and an ankle replacement system, both harnessing advanced 3D printing techniques to cater to diverse patient needs. Notably, these products have obtained regulatory clearance from the U.S. Food and Drug Administration (FDA) under the 510(k) premarket pathway, underscoring their safety and efficacy.
In its pursuit of continuous growth and innovation, restor3d has recently expanded its presence in Research Triangle Park, unveiling a state-of-the-art 50,000-square-foot facility that serves as a hub for office operations and manufacturing activities. This strategic move reflects the company’s commitment to scaling its production capabilities and enhancing its research and development efforts to meet the evolving demands of the orthopedic market.
Partner Group’s recognition of restor3d’s unique value proposition in addressing critical unmet needs within the orthopedic landscape further solidifies the company’s position as a frontrunner in the realm of personalized orthopedic solutions. With Partner Group’s extensive financial resources and industry expertise, restor3d is well-positioned to drive forward its mission of revolutionizing orthopedic care through innovative 3D-printed implants tailored to individual patient requirements.
Takeaways:
– Restor3d’s $104 million investment round, led by Partner Group, highlights the growing interest in 3D printing technologies for orthopedic applications.
– The company’s focus on personalized orthopedic solutions through customized implants has garnered praise for its potential to enhance surgical outcomes and patient recovery.
– Regulatory clearances from the FDA for its flagship products underscore restor3d’s commitment to safety and efficacy in orthopedic innovation.
– The expansion of restor3d’s manufacturing facility signals a strategic move towards bolstering production capabilities and fostering research and development initiatives.
Tags: regulatory
Read more on ncbiotech.org